Apr 2, 2020

Athera Biotechnologies announces that the last patient has been dosed in their Phase 2 study with ATH3G10, a new candidate drug for prevention of heart failure. The study completed recruitment by including 82 patients with STEMI and aims for results to be presented in 2020. The target of the study with ATH3G10 was to include approximately 80 patients with acute myocardial infarction and high risk to develop heart failure. Treatment effect is measured by Magnetic Resonance Imaging (MRI) scans that correlate with development of heart failure. A total of 15 hospitals in Sweden, Denmark and The Netherlands have enabled the full recruitment of the study. The proof-of-concept study randomized acute MI patients to one dose of either ATH3G10 or placebo, immediately after the standard of care catheter intervention at acute cardiology units in hospital. The study was started in 2019 with the first patient recruited in April. The extraordinary challenges of the ongoing Covid-19 outbreak Despite current challenges within the health care systems following the Corona-virus outbreak, study recruitment has now been completed according to plan and 82 patients have entered the trial. The study protocol will proceed into the follow-up period, where patients come back for a second MRI-imaging and for regular safety check-up. The study is designed to show if treatment with ATH3G10 significantly decreases the probability for heart failure following myocardial infarction, compared to placebo. “We are very grateful that we were able to complete recruitment of patients to the study according to our plans,” says James Hall, CEO of Athera. “We owe the teams at the acute cardiology units and at the MRI units great respect for their outstanding dedication and active conduct in the study. This has been one of the quickest trials to recruit in this patient population in recent years. We continue to rely heavily on the involvement of the teams and participating patients throughout the follow-up period, despite the extraordinary challenges of the ongoing Covid-19 outbreak.” Photo: Athera Biotechnologies January 20, 2014 Trialbee has developed a web based platform and methodology which enable the Novo Nordisk to perform fast and effective patient recruitment to specific clinical trials. Trialbee helps reduce the time required for recruitment resulting in important efficiency gains for the pharmaceutical company. Novo Nordisk will use Trialbee’s services for e-recruitment… January 12, 2018 The company has received authorization to conduct a phase I/II clinical study on the quadrivalent influenza vaccine candidate Immunose FLU, a novel nose drop formulation based on the company´s technology Endocine and inactivated split antigens. Eurocine Vaccines submitted applications to the Swedish Medical Products Agency, MPA, and to the Ethics… August 29, 2019 The company has announced positive Phase II MERECA results, including complete tumor responses in metastatic renal cell carcinoma patients. The study’s objective was to evaluate the therapeutic impact of combining ilixadencel with Sutent (sunitinib). The most important outcome was achieving five complete responses, defined as eradication of the cancerous tumor… May 19, 2016 Benralizumab, AZ’s potential new medicine and anti-eosinophil monoclonal antibody, has been well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials. This demonstrates significant reductions in the annual asthma exacerbation rate compared to placebo. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said:… Editor in Chief